Skip to main content
Erschienen in:

06.07.2019 | Original Article – Clinical Oncology

Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study

verfasst von: Alessandro Parisi, Alessio Cortellini, Michela Roberto, Olga Venditti, Daniele Santini, Emanuela Dell’Aquila, Marco Stellato, Paolo Marchetti, Mario Alberto Occhipinti, Federica Zoratto, Federica Mazzuca, Nicola Tinari, Michele De Tursi, Laura Iezzi, Clara Natoli, Margherita Ratti, Claudio Pizzo, Michele Ghidini, Giampiero Porzio, Corrado Ficorella, Katia Cannita

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims and methods

This multicenter retrospective study aims to evaluate the correlations between Body Weight Loss (BWL), Body Mass Index (BMI) and clinical outcomes (ORR, PFS, and OS) of advanced gastric cancer (aGC) patients treated with second-line ramucirumab-based therapy in a “real-life” setting.

Results

From December 2014 to October 2018, 101 consecutive aGC patients progressed to a first-line chemotherapy were treated with ramucirumab alone (10.9%) or in combination with paclitaxel (89.1%). Median BMI was 21.2 kg/m2 and mBWL since first-line treatment commencement was 4.5%. Among 53 patients who underwent primary tumor resection (PTR), 73.6% experienced BWL, while 26.4% did not experience BWL (p = 0.0429). Patients who underwent PTR had a significantly higher probability of experiencing BWL (yes vs no) [OR = 2.35 (95% CI 1.02–5.42), p = 0.0439]. Among the 89 evaluable patients, ORR was 26.9% (95% CI 17.2–40.1). At a median follow-up of 17.3 months, mPFS was 5.4 months (95% CI 3.6–6.8) and mOS was 8.7 months (95% CI 7.3–11.9). In the multivariate analysis, only ECOG-PS and BMI were confirmed independent predictors for shorter PFS [HR = 1.69 (95% CI 1.01–2.82), p = 0.04] [HR = 1.97 (95% CI 1.12–3.46), p = 0.01] and OS [HR = 1.69 (95% CI 1.01–2.83), p = 0.04] [HR = 2.08 (95% CI 1.17–3.70), p = 0.01].

Conclusion

Efficacy of ramucirumab is confirmed in this “real-life” analysis. BWL seems not to have correlations with clinical outcomes in these patients, while BMI and ECOG-PS remain major prognostic factors. A possible explanation for the lack of prognostic effect of BWL might be the proportion of patients subjected to PTR in this series (52.5%).
Literatur
Zurück zum Zitat Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17(12):1697–1708CrossRefPubMed Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17(12):1697–1708CrossRefPubMed
Zurück zum Zitat Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemoterapy versus chemoterapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open label, randomised controlled trial. Lancet 376(9742):687–697CrossRefPubMed Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemoterapy versus chemoterapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open label, randomised controlled trial. Lancet 376(9742):687–697CrossRefPubMed
Zurück zum Zitat Cortellini A, Cannita K, Parisi A, Venditti O, Lanfiuti Baldi P, De Berardis B et al (2018) Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: a single institution experience with the FD/FOx regimen. Oncol Rep 40(2):803–812. https://doi.org/10.3892/or.2018.6475 (Epub 2018 Jun 6)CrossRefPubMed Cortellini A, Cannita K, Parisi A, Venditti O, Lanfiuti Baldi P, De Berardis B et al (2018) Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: a single institution experience with the FD/FOx regimen. Oncol Rep 40(2):803–812. https://​doi.​org/​10.​3892/​or.​2018.​6475 (Epub 2018 Jun 6)CrossRefPubMed
Zurück zum Zitat Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc (Series B) 74:187–200 Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc (Series B) 74:187–200
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRef
Zurück zum Zitat Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39CrossRefPubMed Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39CrossRefPubMed
Zurück zum Zitat Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC et al (2017) Prognostic factor analysis of overall survival in gastric cancer from two phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data. J Gastric Cancer. 17(2):132–144CrossRefPubMedCentralPubMed Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC et al (2017) Prognostic factor analysis of overall survival in gastric cancer from two phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data. J Gastric Cancer. 17(2):132–144CrossRefPubMedCentralPubMed
Zurück zum Zitat Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ, Dutch Gastric Cancer Group (2002) Value of palliative resection in gastric cancer. Br J Surg. 89(11):1438–1443CrossRefPubMed Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ, Dutch Gastric Cancer Group (2002) Value of palliative resection in gastric cancer. Br J Surg. 89(11):1438–1443CrossRefPubMed
Zurück zum Zitat Jun DH, Kim BJ, Park JH, Kim JG, Chi KC, Park JM et al (2016) Preoperative body mass index may determine the prognosis of advanced gastric cancer. Nutr Cancer. 68(8):1295–1300 (Epub 2016 Oct 7)CrossRefPubMed Jun DH, Kim BJ, Park JH, Kim JG, Chi KC, Park JM et al (2016) Preoperative body mass index may determine the prognosis of advanced gastric cancer. Nutr Cancer. 68(8):1295–1300 (Epub 2016 Oct 7)CrossRefPubMed
Zurück zum Zitat Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG et al (2018) Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer 21(5):819–830. https://doi.org/10.1007/s10120-018-0806-1 (Epub 2018 Feb 9)CrossRefPubMed Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG et al (2018) Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer 21(5):819–830. https://​doi.​org/​10.​1007/​s10120-018-0806-1 (Epub 2018 Feb 9)CrossRefPubMed
Zurück zum Zitat Kaplan EL, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457–481CrossRef Kaplan EL, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457–481CrossRef
Zurück zum Zitat Kubo H, Komatsu S, Ichikawa D, Kawaguchi T, Kosuga T, Okamoto K et al (2016) Impact of body weight loss on recurrence after curative gastrectomy for gastric cancer. Anticancer Res 36(2):807–813PubMed Kubo H, Komatsu S, Ichikawa D, Kawaguchi T, Kosuga T, Okamoto K et al (2016) Impact of body weight loss on recurrence after curative gastrectomy for gastric cancer. Anticancer Res 36(2):807–813PubMed
Zurück zum Zitat Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730CrossRefPubMed Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730CrossRefPubMed
Zurück zum Zitat Moriwaki Y, Kunisaki C, Kobayashi S, Harada H, Imai S, Kasaoka C (2003) Does body mass index (BMI) influence morbidity and long-term survival in gastric cancer patients after gastrectomy? Hepatogastroenterology. 50(49):284–288PubMed Moriwaki Y, Kunisaki C, Kobayashi S, Harada H, Imai S, Kasaoka C (2003) Does body mass index (BMI) influence morbidity and long-term survival in gastric cancer patients after gastrectomy? Hepatogastroenterology. 50(49):284–288PubMed
Zurück zum Zitat Schemper M, Smith TL (1997) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343–346CrossRef Schemper M, Smith TL (1997) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343–346CrossRef
Zurück zum Zitat Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S et al (2015) Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium. J Clin Oncol 33(33):3874–3879CrossRefPubMed Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S et al (2015) Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium. J Clin Oncol 33(33):3874–3879CrossRefPubMed
Zurück zum Zitat Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235CrossRefPubMed Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235CrossRefPubMed
Metadaten
Titel
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study
verfasst von
Alessandro Parisi
Alessio Cortellini
Michela Roberto
Olga Venditti
Daniele Santini
Emanuela Dell’Aquila
Marco Stellato
Paolo Marchetti
Mario Alberto Occhipinti
Federica Zoratto
Federica Mazzuca
Nicola Tinari
Michele De Tursi
Laura Iezzi
Clara Natoli
Margherita Ratti
Claudio Pizzo
Michele Ghidini
Giampiero Porzio
Corrado Ficorella
Katia Cannita
Publikationsdatum
06.07.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-019-02971-7

Weitere Artikel der Ausgabe 9/2019

Journal of Cancer Research and Clinical Oncology 9/2019 Zur Ausgabe

Neu im Fachgebiet Onkologie

Muskeln trainieren gegen Nervenschäden durch Chemotherapie

17.07.2024 Nebenwirkungen der Krebstherapie Nachrichten

Chemotherapien können die Nerven schädigen und damit die Lebensqualität von Betroffenen zusätzlich einschränken. Wer aber auf die richtige Art trainiert, kann das absolute Risiko für Neuropathien um bis zu 40% senken.

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen. Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom etwa hatten das beste Outcome, wenn die PD-1-Inhibitor-Infusionen in den Wintermonaten starteten.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.